Key result
Padua Classification categorizes cardiomyopathies into three groups to improve diagnostic accuracy and treatment outcomes.
Why the study?
A novel classification was proposed to enhance diagnostic accuracy and support disease-specific therapeutic strategies to improve patient management and outcomes.
Key points are not available for this paper at this time.
Design
Review
Introduces the Padua Classification for cardiomyopathies, integrating pathobiological and clinical features to improve diagnostic accuracy and patient management.
The newly proposed classification of cardiomyopathies, referred to as ‘the Padua Classification’, is based on both pathobiological basis (genetics, molecular biology, and pathology) and clinical features (morpho-functional and structural ventricular remodelling as evidenced by cardiac magnetic resonance). Cardiomyopathies are grouped into tree main categories and characterized by a designation combining both ‘anatomical’ and ‘functional’ features: hypertrophic/restrictive, dilated/hypokinetic, and scarring/arrhythmogenic; each cardiomyopathy group includes either genetic or non-genetic aetiologic variants. This novel approach aims to enhance the diagnostic accuracy and to support ‘disease-specific’ therapeutic strategies, with the objective to improve patient management and outcome.
No takes yet. Share an insight, caveat, or question.
Corrado et al. (2025) studied this question. The Padua Classification categorizes cardiomyopathies into hypertrophic/restrictive, dilated/hypokinetic, and scarring/arrhythmogenic groups to improve diagnostic accuracy and treatment outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: